CHUNLI MEDICAL (01858) has announced a proposal to re-appoint Daxin Certified Public Accountants (Special General Partnership) as the company's financial and internal control auditor for the 2026 fiscal year. The decision, aimed at maintaining continuity and stability in the audit process, was recommended by the board's audit committee and received prior approval from all independent directors. The appointment period will commence from the date of the resolution passed at the 2025 annual general meeting and will conclude upon the holding of the 2026 annual general meeting. The board of directors will seek authorization from the shareholders' meeting for the management to finalize the specific remuneration with Daxin, taking into account the audit workload for 2026 and prevailing market rates.